Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer’s disease mouse model

Clinical trials with rosiglitazone, a potent agonist at peroxisome proliferator-activated receptor gamma (PPARγ) suggest an improvement of cognitive function in Alzheimer’s disease (AD) patients. The mechanisms mediating this potential beneficial effect remain to be fully elucidated. In mice overexp...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biochemical and biophysical research communications 2009-02, Vol.379 (2), p.406-410
Hauptverfasser:	Escribano, Luis, Simón, Ana-María, Pérez-Mediavilla, Alberto, Salazar-Colocho, Pablo, Río, Joaquín Del, Frechilla, Diana
Format:	Artikel
Sprache:	eng
Schlagworte:	60 APPLIED LIFE SCIENCES Administration, Oral Alzheimer Disease - blood Alzheimer Disease - complications Alzheimer Disease - genetics Alzheimer’s disease Amyloid beta-Protein Precursor - genetics Amyloid beta-Protein Precursor - metabolism Animals BLOOD PLASMA CLINICAL TRIALS CORTICOSTERONE Down-Regulation GENE REGULATION Glucocorticoids HIPPOCAMPUS Hippocampus - drug effects Hippocampus - metabolism HUMAN POPULATIONS Humans Memory Memory Disorders - blood Memory Disorders - genetics Memory Disorders - prevention & control Mice Mice, Transgenic MUTANTS NERVOUS SYSTEM DISEASES Peroxisome proliferator-activated receptor-γ PPAR gamma - agonists PPAR gamma - metabolism RECEPTORS Receptors, Glucocorticoid - blood Receptors, Glucocorticoid - metabolism Thiazolidinediones - administration & dosage Thiazolidinediones - therapeutic use TRANSGENIC MICE
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!